Omeros Stock Soars Following Novo Nordisk Licensing Deal

On October 15, 2025, Omeros Corporation (NASDAQ: OMER) experienced a significant stock surge of approximately 146%, closing at around $10.11 after opening near $11.53. This increase followed the announcement of a landmark licensing deal with Novo Nordisk (NYSE: NVO), which will acquire exclusive global rights to Omeros's investigational drug zaltenibart (OMS906), a MASP-3 inhibitor targeting rare blood and kidney disorders. The agreement is valued at up to $2.1 billion, with Omeros receiving an upfront payment of $340 million, alongside potential milestone payments and tiered royalties.

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?Omeros triples after signing up to $2.1 billion licensing deal with Novo NordiskOmeros set for best day ever on signing up to $2.1 billion licensing deal with NovoNovo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

With zaltenibart licensed to Novo Nordisk, Omeros is refocusing on its lead asset, narsoplimab (OMS721), an antibody for transplant-associated thrombotic microangiopathy (TA-TMA). The U.S. Food and Drug Administration (FDA) has accepted Omeros's resubmitted Biologics License Application (BLA), with a new target decision date set for December 26, 2025. In Europe, the European Medicines Agency (EMA) has validated Omeros's application for narsoplimab, with an opinion expected by mid-2026.

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?Omeros triples after signing up to $2.1 billion licensing deal with Novo NordiskNovo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to KnowOmeros set for best day ever on signing up to $2.1 billion licensing deal with Novo

Market analysts have responded positively to the deal, with D. Boral Capital reiterating a "Buy" rating and projecting a target price of $36, indicating a potential upside of approximately 250%. Broker consensus suggests a moderate buy, with an average one-year target around $18, and some projections suggesting Omeros could reach over $30 by 2026 if milestones are met.

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

The deal with Novo Nordisk not only provides immediate financial relief but also positions Omeros for future growth. Novo plans to initiate a global Phase 3 program for zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated disorders. However, Omeros faces significant risks, including high research and development costs, regulatory hurdles, and a historically tight cash position. Despite the cash influx from the licensing deal, Omeros remains a development-stage biotech company, and its long-term viability hinges on successful execution of its pipeline projects.

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Novo Nordisk's Chief Scientific Officer, Martin Lange, praised zaltenibart's "novel mode of action" and its potential advantages over existing therapies. Omeros CEO Gregory Demopulos expressed optimism about the partnership, stating that he is "pleased to enter into this agreement with Novo Nordisk" and believes it will "unlock the potential" of zaltenibart.

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

• “offers timely validation of Omeros’ pipeline” — Fierce Biotech

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

• “pleased to enter into this agreement with Novo Nordisk” — Gregory Demopulos, CEO of Omeros

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

• “novel mode of action” — Martin Lange, CSO of Novo Nordisk

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

While Omeros's stock saw a significant increase, reports on the exact percentage varied, with some sources indicating a rise of up to 195.1% during trading. Additionally, the average analyst price target before the deal was reported at approximately $5.40, suggesting a substantial shift in market expectations following the announcement.

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

In summary, the licensing agreement with Novo Nordisk has fundamentally altered Omeros's financial outlook and operational focus, providing a cash buffer and validating its drug development efforts.

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?